Abstract: Disclosed are methods, systems, components, and compositions for synthesis of sequence defined polymers. The methods, systems, components, and compositions may be utilized for incorporating novel substrates that include non-standard amino acid monomers and non-amino acid monomers into sequence defined polymers. As disclosed herein, the novel substrates may be utilized for acylation of tRNA via flexizyme catalyzed reactions. The tRNAs thus acylated with the novel substrates may be utilized in synthesis platforms for incorporating the novel substrates into a sequence defined polymer.

Abstract: A multiplexer includes a charging circuit; a plurality of sampling switches receiving a plurality of input signals; and a plurality of boosting circuits connected between the sampling switches and the charging circuit and sharing the charging circuit. First and second charging switches of the charging circuit are controlled by a first clock signal. Each of the boosting circuits includes a first boosting switch connected to a first node of the charging circuit and a gate of one of the sampling switches, a second boosting switch connected between a second node of the charging circuit and the one sampling switch, and a level shifter configured to control the first boosting switch and the second boosting switch in response to a second clock signal and a selection signal.

Abstract: A mote includes an optical receiver that wirelessly receives a power and data signal in form of NIR light energy within a patient and converts the NIR light energy to an electrical signal having a supply voltage. A control module supplies the supply voltage to power devices of the mote. A clock generation circuit locks onto a target clock frequency based on the power and data signal and generates clock signals. A data recovery circuit sets parameters of one of the devices based on the power and data signal and a first clock signal. An amplifier amplifies a neuron signal detected via an electrode inserted in tissue of the patient. A chip identifier module, based on a second clock signal, generates a recorded data signal based on a mote chip identifier and the neuron signal. A driver transmits the recorded data signal via a LED or a RF transmitter.

Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods utilizing Meteorin-like (METRNL), C-X-C Motif Chemokine Receptor 6 (CXCR6) and/or endogenous C-X-C Motif Ligand 16 (CXCL16) as immune-oncology targets. Accordingly, in one aspect, the present invention provides compositions and methods directed to the knockout of METRNL, CXCR6 and/or CXCL16 expression in a cell. In particular embodiments, the cell is a T cell. In a specific embodiment, the present invention provides an engineered T-cell comprising disruption in the METRNL, CXCR6 and/or CXCL16 gene sequence. In another embodiment, an engineered T-cell comprises (a) at least one chimeric antigen receptor (CAR); and (b) at least one genomic disruption of METRNL, CXCR6 and/or CXCL16. In certain embodiments, the genomic disruption is performed using a CRSIPR endonuclease system.

Abstract: The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.

Abstract: Methods and compositions for treating a glioblastoma (GBM) by administering a composition comprising a hydrogel and an anti-programmed cell death protein 1 (PD-1) antibody to one or more draining lymph nodes (DLNs) of a subject in need of treatment thereof are disclosed.

Abstract: The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.

Abstract: A camera mount includes a pivotable assembly of a pair of arms and a pocket into which an end of one of the arms is inserted, in one of a plurality of discrete orientations. The arms are pivotably joined to one another by a fastener and permitted to be aligned at one of a plurality of angles. The camera mount is installed in a track, a rail or another system mounted to a fixture of a materials handling facility or another environment, and a camera module is mounted to another end of one of the arms. A position of the camera module is selected by installing the camera mount into a desired location on the track, the rail or the other system. An orientation of the camera module is selected by selecting the one of the plurality of discrete orientations and aligning the arms at one of the plurality of angles.

Abstract: A light emitting diode package including: a housing; a light emitting diode chip arranged in the housing; a wavelength conversion unit arranged on the light emitting diode chip; a first fluorescent substance distributed inside the wavelength conversion unit and emitting light having a peak wavelength in the cyan wavelength band; and a second fluorescent substance distributed inside the wavelength conversion unit and emitting light having a peak wavelength in the red wavelength band, wherein the peak wavelength of light emitted from the light emitting diode chip is located within a range of 415 nm to 430 nm.

Abstract: Described herein are functionalized garments that can be worn on the torso of a subject and can be configured with varying zones or areas of compressions and can provide increased signal-to-noise ratios and reduced motion artifacts in areas while allowing a substantially unimpeded freedom of motion.

Abstract: A light emitting diode package includes: a housing; a light emitting diode chip arranged in the housing; a wavelength conversion unit arranged on the light emitting diode chip; a first fluorescent substance distributed inside the wavelength conversion unit and emitting light having a peak wavelength in the cyan wavelength band; and a second fluorescent substance distributed inside the wavelength conversion unit and emitting light having a peak wavelength in the red wavelength band, wherein the peak wavelength of light emitted from the light emitting diode chip is located within a range of 415 nm to 430 nm.

Abstract: The present invention relates to the field of inflammation. More specifically, the present invention provides compositions and methods for treating cerebral inflammation and associated sequelae thereof including cerebral vasospasm. In one embodiment, a method for treating cerebral vasospasm in a patient comprises the step of administering to the patient a PD-1 agonist, wherein a blood sample obtained from the patient comprises elevated PD-1 expression on monocytes relative to a control.

Abstract: A marker for imaging includes a bio-dissolvable material and a contrast agent configured to provide contrast during an imaging procedure. A method can include forming a marker for imaging from a bio-dissolvable material and impregnating the bio-dissolvable material with a contrast agent. A method can include implanting a bio-dissolvable marker for imaging into a patient.

Abstract: The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.

Abstract: A light emitting diode package includes: a housing; a light emitting diode chip arranged in the housing; a wavelength conversion unit arranged on the light emitting diode chip; a first fluorescent substance distributed inside the wavelength conversion unit and emitting light having a peak wavelength in the cyan wavelength band; and a second fluorescent substance distributed inside the wavelength conversion unit and emitting light having a peak wavelength in the red wavelength band, wherein the peak wavelength of light emitted from the light emitting diode chip is located within a range of 415 nm to 430 nm.

Abstract: The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.

Abstract: A light emitting diode package includes: a housing; a light emitting diode chip arranged in the housing; a wavelength conversion unit arranged on the light emitting diode chip; a first fluorescent substance distributed inside the wavelength conversion unit and emitting light having a peak wavelength in the cyan wavelength band; and a second fluorescent substance distributed inside the wavelength conversion unit and emitting light having a peak wavelength in the red wavelength band, wherein the peak wavelength of light emitted from the light emitting diode chip is located within a range of 415 nm to 430 nm.

Abstract: Described herein are functionalized garments that can be worn on the torso of a subject and can be configured with varying zones or areas of compressions and can provide increased signal-to-noise ratios and reduced motion artifacts in areas while allowing a substantially unimpeded freedom of motion.